Pityriasis

Researchers are evaluating the safety and effectiveness of Deucravacitinib (BMS-986165) for treating Pityriasis Rubra Pilaris (PRP), a skin condition, in this Phase 2 study. The study also aims to identify unique biomarkers of PRP using single-cell RNA sequencing to predict patient responses to treatment. The main measures of effectiveness include changes in Investigator Global Assessment (IGA), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Numeric Rating Scale (NRS) for itch, and Skindex-16 at 24 weeks. Participants will receive Deucravacitinib orally at a dose of 6 mg twice daily for 24 weeks. The treatment is given continuously during this period with no placebo or comparison group described. The study focuses on patients with moderate to severe PRP who have not responded adequately to topical therapies and are candidates for systemic treatment. Throughout the study, participants will undergo evaluations of their skin condition and quality of life using various scales and questionnaires at baseline and at 24 weeks. Safety and treatment effects will be monitored, including changes in PASI scores. The total duration for each participant is 24 weeks of treatment with assessments aimed at understanding treatment impact and identifying biomarkers related to response.